BXQ-350
Clinical Trials
Regulated by the U.S. Food and Drug Administration
LEARN MORE ABOUT OUR CLINICAL TRIALS
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (ASIST) – Active, not recruiting.
BXQ-350 Pharmacokinetic/ Pharmacodynamic Study in Cancer Patients (RETRO) – Active, not recruiting.
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) – Completed.
Continued Treatment for Participants Enrolled in Studies of BXQ-350 (ETERNITI) – Completed.
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors – Completed.
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors (KOURAGE) – Completed.
What is BXQ-350?
BXQ-350 is an investigational therapeutic that is not currently approved for clinical use. Access is limited to participants in authorized clinical trials. If you are interested in learning more about BXQ-350, please contact [email protected]. We aim to respond to all inquiries within 5 business days.